Bristol-Myers Squibb Co
BMY54.670USD
-0.040-0.07%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
111.31BMarket Cap
18.40P/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Co Info
Ticker SymbolBMY
Company nameBristol-Myers Squibb Co
IPO dateMar 17, 1980
CEOBoerner (Christopher S)
Number of employees34100
Security typeOrdinary Share
Fiscal year-endMar 17
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Ticker SymbolBMY
IPO dateMar 17, 1980
CEOBoerner (Christopher S)
Company Executives of Bristol-Myers Squibb Co
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
Other
3.47B
28.29%
By RegionUSD
Name
Revenue
Proportion
United States
8.52B
69.44%
International
3.48B
28.37%
other
270.00M
2.20%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
Other
3.47B
28.29%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
Other
74.21%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
Other
74.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.02%
Investment Advisor/Hedge Fund
25.70%
Research Firm
2.97%
Pension Fund
2.51%
Hedge Fund
2.51%
Bank and Trust
2.22%
Sovereign Wealth Fund
1.74%
Insurance Company
0.19%
Family Office
0.06%
Other
18.08%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
3973
1.68B
84.73%
-171.91K
2025Q3
4147
1.68B
85.10%
-5.79M
2025Q2
4212
1.69B
83.90%
+15.56M
2025Q1
4284
1.67B
82.20%
-238.41K
2024Q4
4280
1.64B
80.20%
+45.34M
2024Q3
4106
1.59B
79.76%
+6.69M
2024Q2
4097
1.58B
82.24%
-51.64M
2024Q1
4107
1.64B
80.22%
+12.13M
2023Q4
4104
1.60B
80.80%
-21.68M
2023Q3
4025
1.62B
80.17%
-24.04M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
193.94M
9.53%
+3.47M
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
99.37M
4.88%
+1.60M
+1.64%
Jun 30, 2025
State Street Investment Management (US)
94.74M
4.65%
-94.48K
-0.10%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
70.80M
3.48%
+10.20M
+16.82%
Jun 30, 2025
JP Morgan Asset Management
67.41M
3.31%
-2.47M
-3.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
46.18M
2.27%
+723.46K
+1.59%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
33.57M
1.65%
-1.60M
-4.55%
Jun 30, 2025
Capital International Investors
66.16M
3.25%
-303.34K
-0.46%
Jun 30, 2025
Columbia Threadneedle Investments (US)
29.38M
1.44%
+350.53K
+1.21%
Jun 30, 2025
PRIMECAP Management Company
22.94M
1.13%
-25.98K
-0.11%
Jun 30, 2025
View more
Related ETFs
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Name
Proportion
VanEck Pharmaceutical ETF
9.15%
First Trust NASDAQ Pharmaceuticals ETF
7.58%
Franklin US Dividend Booster Index ETF
5.08%
WBI Power Factor High Dividend ETF
4.88%
VanEck Morningstar Wide Moat Value ETF
4.34%
iShares U.S. Pharmaceuticals ETF
4.31%
Schwab U.S. Dividend Equity ETF
3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
3.68%
ETC 6 Meridian Mega Cap Equity ETF
3.58%
Brookstone Value Stock ETF
3.48%
View more
VanEck Pharmaceutical ETF
Proportion9.15%
First Trust NASDAQ Pharmaceuticals ETF
Proportion7.58%
Franklin US Dividend Booster Index ETF
Proportion5.08%
WBI Power Factor High Dividend ETF
Proportion4.88%
VanEck Morningstar Wide Moat Value ETF
Proportion4.34%
iShares U.S. Pharmaceuticals ETF
Proportion4.31%
Schwab U.S. Dividend Equity ETF
Proportion3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
Proportion3.68%
ETC 6 Meridian Mega Cap Equity ETF
Proportion3.58%
Brookstone Value Stock ETF
Proportion3.48%
Dividend
A total of
22.71B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 10, 2025
BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option
Jan 02, 2026
Feb 02, 2026
Jan 02, 2026
Sep 17, 2025
BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option
Oct 03, 2025
Nov 03, 2025
Oct 03, 2025
Jun 17, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option
Jul 03, 2025
Aug 01, 2025
Jul 03, 2025
Mar 03, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option
Apr 04, 2025
May 01, 2025
Apr 04, 2025
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Bristol-Myers Squibb Co?
The top five shareholders of Bristol-Myers Squibb Co are:
The Vanguard Group, Inc. holds 193.94M shares, accounting for 9.53% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 99.37M shares, accounting for 4.88% of the total shares.
State Street Investment Management (US) holds 94.74M shares, accounting for 4.65% of the total shares.
Charles Schwab Investment Management, Inc. holds 70.80M shares, accounting for 3.48% of the total shares.
JP Morgan Asset Management holds 67.41M shares, accounting for 3.31% of the total shares.
The Vanguard Group, Inc. holds 193.94M shares, accounting for 9.53% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 99.37M shares, accounting for 4.88% of the total shares.
State Street Investment Management (US) holds 94.74M shares, accounting for 4.65% of the total shares.
Charles Schwab Investment Management, Inc. holds 70.80M shares, accounting for 3.48% of the total shares.
JP Morgan Asset Management holds 67.41M shares, accounting for 3.31% of the total shares.
What are the top three shareholder types of Bristol-Myers Squibb Co?
The top three shareholder types of Bristol-Myers Squibb Co are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Bristol-Myers Squibb Co (BMY)?
As of 2025Q4, 3973 institutions hold shares of Bristol-Myers Squibb Co, with a combined market value of approximately 1.68B, accounting for 84.73% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.37%.
What is the biggest source of revenue for Bristol-Myers Squibb Co?
In FY2025Q2, the Eliquis business generated the highest revenue for Bristol-Myers Squibb Co, amounting to 3.68B and accounting for 30.00% of total revenue.
